(Total Views: 519)
Posted On: 08/21/2017 3:56:22 PM
Post# of 72446
In the most recent PR, Leo said "With next steps for our IBD program in planning". That tells me the B-UP negotiations are ongoing. In the June CC, Dr. B said other B-UP formulations require a lot of investment.
"So, we're already talking with formulation people to get that kind of stuff done, but again that requires a lot of investment and we're cautious about when we pull the trigger on those things. So, we spend our money wisely, but it's not just a pipe dream. We're actively working towards it at this point."
He also said for the oral formulation, BPs have the pill technology but lack the drug.
"So, I think it would not be reinventing the wheel on how to do that. A lot of big pharms right now understand that themselves. Some actually have the technology available, but maybe lacking in terms of the right drug candidate with enough horsepower to treat the disease.
So that really just sets us up as Leo mentioned again toward a partnership. If that's appreciated, I think we could be in very good shape to move that in that direction without having to reinvent the wheel and really coming across the finish line effectively."
https://seekingalpha.com/article/4080068-inno...art=single
If you put two and two together, you should see the next steps for B-UP require BP's help. That's why I'm confident that we'll see a big deal similar to J&J / Protagonist's $990M deal with $50M upfront for a preclinical IBD drug.
"So, we're already talking with formulation people to get that kind of stuff done, but again that requires a lot of investment and we're cautious about when we pull the trigger on those things. So, we spend our money wisely, but it's not just a pipe dream. We're actively working towards it at this point."
He also said for the oral formulation, BPs have the pill technology but lack the drug.
"So, I think it would not be reinventing the wheel on how to do that. A lot of big pharms right now understand that themselves. Some actually have the technology available, but maybe lacking in terms of the right drug candidate with enough horsepower to treat the disease.
So that really just sets us up as Leo mentioned again toward a partnership. If that's appreciated, I think we could be in very good shape to move that in that direction without having to reinvent the wheel and really coming across the finish line effectively."
https://seekingalpha.com/article/4080068-inno...art=single
If you put two and two together, you should see the next steps for B-UP require BP's help. That's why I'm confident that we'll see a big deal similar to J&J / Protagonist's $990M deal with $50M upfront for a preclinical IBD drug.
(5)
(0)
